Abstract:The methods currently used for the detection of ANA have been analyzed, with emphasis on their practical application to the diagnosis of the CTD. The use of the indirect IF-ANA test was recommended as a screening procedure to detect ANA. The need to standardize the technique using a single substrate and fluorescent conjugates with uniform F/P ratios was stressed. Most importantly, the value of titrating ANA for the diagnosis of the CTD was discussed. ANA titers higher than 1/500 are usually very significant clinically, often found in spontaneous or drug-induced SLE and few other CTD. The immunologic aspects of ANA and their potential value as aids in the diagnosis and management of the CTD were discussed. Anti-nDNA antibodies have been found to have a high degree of specificity for SLE and high titers of these antibodies correlate well with low levels of serum complement and severity of kidney involvement. The spectrum of ANA in the sera from patients with SLE has been expanded with the finding of anti-Sm antibodies which, when detected by gel precipitation with prototype serum, have been found so far only in SLE. Some of these antibodies have been found to have prognostic significance. Patients with MCTD and a group of patients with SLE have high titers of serum ANA with specificity for an RNase-sensitive component of ENA. The group of SLE patients defined by the presence of these antibodies (anti-Mo) have a better prognosis and in general develop only mild nephritis or have no kidney involvement at all. High titers of pure antinucleolar antibodies probably are found almost exclusively in the sera of patients with scleroderma. Some ANA have organ specificity, and GS-ANA have been found in all patients with Felty's syndrome and in a large proportion of patients with RA. One of the great advances in the field has been the recognition that ANA can be induced in the human and in experimental animals by the use of a number of therapeutic agents. Some of these agents can also induce a clinical picture resembling spontaneous SLE, though kidney involvement does not occur or is extremely mild. It is interesting that the whole spectrum of ANA can be found in drug-induced LE except anti-nDNA antibodies which have been associated to the pathogenesis of immune complex nephritis in spontaneous SLE. There is no doubt that research on ANA has contributed a great deal to the understanding of the CTD and will continue to be a valuable tool for the clinician and the investigator.

Effect of antinuclear antibody positivity on antineutrophil cytoplasmic antibody results by indirect immunofluorescence assay

Pathogenesis and treatment progress of antineutrophil cytoplasmic antibody-associated vasculitis

Spectrum of Disease in Patients with Positive Antineutrophil Cytoplasmic Antibodies in General Hospitals

History of antineutrophil cytoplasmic autoantibodies

Clinical Feature Analysis of 190 Patients with Anti-Neutrophil Cytoplasmic Antibodies Associated Vasculitis

An analysis of multi-system involvement and renal pathology of anti-neutrophil cytoplasmic autoantibodies-related vasculitis]

Antinuclear antibodies in neurology and their clinical application

Antinuclear antibodies (ANA): immunologic and clinical significance

[Specific antibodies of soluble nuclear antigens in autoimmune vasculitis]

Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis

Cinical and Pathological Characteristics of Chinese Patients with Antineutrophil Cytoplasmic Autoantibody Associated Systemic Vasculitides: A Study of 426 Patients from A Single Centre

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Glimpse into The Future

Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies.

Clinicopathological Features and Outcomes of IgA Nephropathy with Serum Antineutrophil Cytoplasmic Autoantibody Positivity

[Management of ANCA-associated vasculitides]

144. GEOGRAPHIC DIFFERENCES IN CLINICAL PRESENTATION AND OUTCOME OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY- ASSOCIATED VASCULITIS: ROLE OF ANTIBODY SPECIFICITY

Diagnosis and management of ANCA-associated vasculitis

Diagnostic accuracy of ANCA serology in ANCA‐associated vasculitis with renal involvement

Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort

Detection of anti-neutrophilic cytoplasmic total antibodies by indirect ELISA and demonstration of its clinical significance

A case report of Cardiovascular Disease caused by Anti-neutrophil Cytoplasmic Antibody (ANCA) -associated vasculitis